Boston Scientific Corporation $BSX Shares Purchased by Midwest Professional Planners LTD.

Midwest Professional Planners LTD. increased its stake in Boston Scientific Corporation (NYSE:BSX) by 1.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,492 shares of the medical equipment provider’s stock after purchasing an additional 653 shares during the quarter. Boston Scientific makes up 1.3% of Midwest Professional Planners LTD.’s investment portfolio, making the stock its 20th largest holding. Midwest Professional Planners LTD.’s holdings in Boston Scientific were worth $4,994,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BSX. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific in the 1st quarter worth approximately $27,000. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Princeton Global Asset Management LLC acquired a new stake in Boston Scientific during the second quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific in the second quarter valued at $37,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 2.1%

Shares of NYSE BSX opened at $102.73 on Monday. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market cap of $152.30 billion, a price-to-earnings ratio of 54.94, a P/E/G ratio of 2.02 and a beta of 0.58. The company’s fifty day moving average is $99.72 and its 200-day moving average is $102.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 over the last quarter. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have issued reports on BSX. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Morgan Stanley increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.